AstraZeneca judgement changes the rules for dominant companies
This article was originally published in Scrip
Executive Summary
On 1 July 2010 the EU General Court handed down its judgement in the long-running saga of AstraZeneca's proton pump inhibitor anti-ulcer product Losec (omeprazole). Although dealing with events that happened almost two decades ago, the case – barring appeal – is set to cast a long shadow over the activities of patent and regulatory professionals.